Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ANX010
MIFTS: 73

Anxiety

Categories: Genetic diseases, Mental diseases, Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Anxiety

About this section

MalaCards integrated aliases for Anxiety:

Name: Anxiety 56 12 29 6 42 39 17 71
Anxiety Disorders 54 43 71
Anxiety Disorder 12 15 17
Anxiety State 12 71
Anxiety Neurosis 71
Anxieties 15

Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Mental diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:2030
OMIM 56 607834
MeSH 43 D001008
NCIt 49 C2878
SNOMED-CT 67 197480006
ICD10 32 F41.8 F41.9
MedGen 41 C0003467
UMLS 71 C0003467 C0003469 C0700613 more
Sources

Summaries for Anxiety

About this section
MedlinePlus : 42 What is anxiety? Anxiety is a feeling of fear, dread, and uneasiness. It might cause you to sweat, feel restless and tense, and have a rapid heartbeat. It can be a normal reaction to stress. For example, you might feel anxious when faced with a difficult problem at work, before taking a test, or before making an important decision. It can help you to cope. The anxiety may give you a boost of energy or help you focus. But for people with anxiety disorders, the fear is not temporary and can be overwhelming. What are anxiety disorders? Anxiety disorders are conditions in which you have anxiety that does not go away and can get worse over time. The symptoms can interfere with daily activities such as job performance, schoolwork, and relationships. What are the types of anxiety disorders? There are several types of anxiety disorders, including Generalized anxiety disorder (GAD).People with GAD worry about ordinary issues such as health, money, work, and family. But their worries are excessive, and they have them almost every day for at least 6 months. Panic disorder. People with panic disorder have panic attacks. These are sudden, repeated periods of intense fear when there is no danger. The attacks come on quickly and can last several minutes or more. Phobias. People with phobias have an intense fear of something that poses little or no actual danger. Their fear may be about spiders, flying, going to crowded places, or being in social situations (known as social anxiety). What causes anxiety disorders? The cause of anxiety is unknown. Factors such as genetics, brain biology and chemistry, stress, and your environment may play a role. Who is at risk for anxiety disorders? The risk factors for the different types of anxiety disorders can vary. For example, GAD and phobias are more common in women, but social anxiety affects men and women equally. There are some general risk factors for all types of anxiety disorders, including Certain personality traits, such as being shy or withdrawn when you are in new situations or meeting new people Traumatic events in early childhood or adulthood Family history of anxiety or other mental disorders Some physical health conditions, such as thyroid problems or arrhythmia What are the symptoms of anxiety disorders? The different types of anxiety disorders can have different symptoms. But they all have a combination of Anxious thoughts or beliefs that are hard to control. They make you feel restless and tense and interfere with your daily life. They do not go away and can get worse over time. Physical symptoms, such as a pounding or rapid heartbeat, unexplained aches and pains, dizziness, and shortness of breath Changes in behavior, such as avoiding everyday activities you used to do Using caffeine, other substances, and certain medicines can make your symptoms worse. How are anxiety disorders diagnosed? To diagnose anxiety disorders, your health care provider will ask about your symptoms and medical history. You may also have a physical exam and lab tests to make sure that a different health problem is not the cause of your symptoms. If you don't have another health problem, you will get a psychological evaluation. Your provider may do it, or you may be referred to a mental health professional to get one. What are the treatments for anxiety disorders? The main treatments for anxiety disorders are psychotherapy (talk therapy), medicines, or both: Cognitive behavioral therapy (CBT) is a type of psychotherapy that is often used to treat anxiety disorders. CBT teaches you different ways of thinking and behaving. It can help you change how you react to the things that cause you to feel fear and anxiety. It may include exposure therapy. This focuses on having you confront your fears so that you will be able to do the things that you had been avoiding. Medicines to treat anxiety disorders include anti-anxiety medicines and certain antidepressants. Some types of medicines may work better for specific types of anxiety disorders. You should work closely with your health care provider to identify which medicine is best for you. You may need to try more than one medicine before you can find the right one. NIH: National Institute of Mental Health

MalaCards based summary : Anxiety, also known as anxiety disorders, is related to generalized anxiety disorder and phobic disorder, and has symptoms including agitation, sleeplessness and mental and behavioral signs and symptoms. An important gene associated with Anxiety is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and G-Beta Gamma Signaling. The drugs Tangerine and Moxonidine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and breast, and related phenotypes are behavior/neurological and integument

Disease Ontology : 12 A cognitive disorder that involves an excessive, irrational dread of everyday situations.

OMIM : 56 Human personality is shaped by genetic and environmental factors, and evidence suggests that the genetic component is highly complex, polygenic, and epistatic. Genetic factors are thought to contribute to 40 to 60% of trait variance. Molecular genetics has tried to identify specific genes for quantitative traits, called quantitative trait loci (QTLs). The QTL concept suggests that complex personality traits or dimensions are not attributable to single genes, but to multiple interacting genes (Reif and Lesch, 2003). Fullerton et al. (2003) stated that psychologists were in agreement that the wide variation in human personalities can be explained by a small number of personality factors, including neuroticism (a measure of emotional stability), which manifests at one extreme as anxiety, depression, moodiness, low self-esteem, and diffidence. They cited a number of studies that had described a relationship between high scores on measures of neuroticism and major depressive disorder. They also noted that theoretical studies had suggested that large samples of randomly ascertained sibs could be used to ascertain phenotypically extreme individuals and thereby increase power to detect genetic linkage in complex traits. See also panic disorder (PAND1; 167870), which is a subtype of anxiety disorder. (607834)

Wikipedia : 74 Anxiety is an emotion characterized by an unpleasant state of inner turmoil, often accompanied by... more...

Sources

Related Diseases for Anxiety

About this section

Diseases related to Anxiety via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1289)
# Related Disease Score Top Affiliating Genes
1 generalized anxiety disorder 35.6 TPH1 SLC6A4 NR3C1 HTR2C HTR2A HTR1A
2 phobic disorder 34.4 SLC6A4 HTR2A HTR1A CRHR1 CRH BDNF
3 panic disorder 34.1 TPH2 TPH1 SLC6A4 HTR2C HTR2A HTR1A
4 agoraphobia 33.8 SLC6A4 HTR2A HTR1A CRH CCKBR BDNF
5 phobia, specific 33.7 SLC6A4 HTR1A CRH
6 obsessive-compulsive disorder 33.7 TPH2 TPH1 SLC6A4 HTR2C HTR2A HTR1A
7 social phobia 33.6 SLC6A4 MIR485 HTR1A BDNF
8 depression 33.5 TPH2 TPH1 SLC6A4 HTR2C HTR2A HTR1A
9 neurotic disorder 33.4 SLC6A4 HTR2A HTR1A BDNF
10 bipolar disorder 33.4 TPH2 TPH1 SLC6A4 NR3C1 HTR2C HTR2A
11 acute stress disorder 33.4 SLC6A4 NR3C1 CRHR1 CRH BDNF
12 post-traumatic stress disorder 33.4 SLC6A4 NR3C1 HTR2A HTR1A CRHR1 CRH
13 major depressive disorder 33.3 TPH2 TPH1 SLC6A4 NR3C1 NPS HTR2C
14 eating disorder 33.2 SLC6A4 HTR2C HTR2A CRH CNR1 BDNF
15 attention deficit-hyperactivity disorder 33.2 TPH2 TPH1 SLC6A4 NR3C1 HTR2C HTR2A
16 schizophrenia 32.9 TPH2 TPH1 SLC6A4 NR3C1 HTR2C HTR2A
17 asperger syndrome 32.8 SLC6A4 CNR1 BDNF
18 mental depression 32.6 TPH2 TPH1 SLC6A4 NR3C1 NPS HTR2C
19 mood disorder 32.4 TPH2 TPH1 SLC6A4 NR3C1 HTR2C HTR2A
20 personality disorder 32.2 TPH2 TPH1 SLC6A4 NR3C1 HTR2C HTR2A
21 dysthymic disorder 32.2 SLC6A4 HTR2A HTR1A CRH BDNF
22 alcohol use disorder 32.1 SLC6A4 HTR2C HTR2A HTR1A CYP3A4 CRHR1
23 alcohol dependence 32.1 TPH2 TPH1 SLC6A4 OPRL1 HTR2C HTR2A
24 substance abuse 32.1 SLC6A4 OPRL1 HTR2A HTR1A CYP2D6 CRHR1
25 postpartum depression 31.8 SLC6A4 NR3C1 HTR1A CRH BDNF
26 autism spectrum disorder 31.8 TPH2 SLC6A4 OPRL1 NR3C1 HTR2C HTR2A
27 autism 31.8 TPH2 TPH1 SLC6A4 HTR2C HTR2A HTR1A
28 anorexia nervosa 31.8 TPH1 SLC6A4 HTR2C HTR2A HTR1A CRH
29 hypochondriasis 31.7 SLC6A4 HTR2C HTR2A HTR1A BDNF
30 somatization disorder 31.7 SLC6A4 HTR2A CRH
31 psychotic disorder 31.7 TPH2 TPH1 SLC6A4 HTR2C HTR2A HTR1A
32 pain agnosia 31.7 OPRL1 NPS HTR1A CYP2D6 CNR1
33 sexual disorder 31.7 SLC6A4 HTR2C HTR2A HTR1A CYP3A4 CYP2D6
34 bipolar i disorder 31.7 TPH2 SLC6A4 HTR2C HTR2A HTR1A BDNF
35 bulimia nervosa 31.7 SLC6A4 HTR2C HTR2A CRH CNR1 BDNF
36 endogenous depression 31.6 TPH1 SLC6A4 NR3C1 HTR2A HTR1A CRHR1
37 irritable bowel syndrome 31.6 TPH1 SLC6A4 HTR2A HTR1A CRHR1 CRH
38 tobacco addiction 31.6 TPH1 SLC6A4 HTR2A CRHR1 CRH CNR1
39 adjustment disorder 31.5 SLC6A4 HTR2A HTR1A BDNF
40 borderline personality disorder 31.5 TPH2 TPH1 SLC6A4 NR3C1 HTR2C HTR2A
41 migraine with or without aura 1 31.5 TPH1 SLC6A4 OPRL1 NPS HTR2C HTR2A
42 constipation 31.5 TPH1 SLC6A4 OPRL1 HTR2A HTR1A CYP3A4
43 drug dependence 31.5 SLC6A4 OPRL1 CRHR1 CRH CNR1 BDNF
44 substance dependence 31.5 TPH1 SLC6A4 OPRL1 CYP2D6 CRHR1 CRH
45 fibromyalgia 31.5 SLC6A4 HTR2A HTR1A CRH BDNF
46 sleep disorder 31.5 SLC6A4 NPS HTR2C HTR2A HTR1A BDNF
47 chronic pain 31.5 USH2A CNR1
48 withdrawal disorder 31.4 OPRL1 HTR1A CRHR1 CRH CNR1
49 premature ejaculation 31.4 SLC6A4 HTR2C HTR1A
50 tic disorder 31.4 TPH2 SLC6A4 HTR2A HTR1A

Comorbidity relations with Anxiety via Phenotypic Disease Network (PDN): (show top 50) (show all 78)


Acute Cor Pulmonale Acute Cystitis
Acute Stress Disorder Adjustment Disorder
Allergic Rhinitis Atrophic Gastritis
Atypical Depressive Disorder Basilar Artery Insufficiency
Benign Essential Hypertension Borderline Personality Disorder
Bronchiectasis Bronchitis
Bronchopneumonia Cerebrovascular Disease
Chronic Pulmonary Heart Disease Chronic Rhinitis
Conn's Syndrome Conversion Disorder
Deficiency Anemia Delusional Disorder
Dependent Personality Disorder Dyskinesia of Esophagus
Dysthymic Disorder Esophagitis
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Gastroesophageal Reflux Generalized Anxiety Disorder
Generalized Atherosclerosis Heart Disease
Histrionic Personality Disorder Hyperlipoproteinemia, Type Iv
Hypertension, Essential Hypertensive Encephalopathy
Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis Syndrome Hypochondriasis
Hypothyroidism Intermediate Coronary Syndrome
Intestinal Obstruction Iron Deficiency Anemia
Irritable Bowel Syndrome Labyrinthitis
Major Depressive Disorder Malignant Essential Hypertension
Meniere Disease Migraine with or Without Aura 1
Mitral Valve Disease Mood Disorder
Narcissistic Personality Disorder Obsessive-Compulsive Disorder

Graphical network of the top 20 diseases related to Anxiety:



Diseases related to Anxiety
Sources

Symptoms & Phenotypes for Anxiety

About this section

Clinical features from OMIM:

607834

UMLS symptoms related to Anxiety:


agitation, sleeplessness, mental and behavioral signs and symptoms, nervousness, feeling tense, feeling jittery, anxiety symptoms

MGI Mouse Phenotypes related to Anxiety:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.13 BDNF CCKBR CNR1 CRH CRHR1 HTR1A
2 integument MP:0010771 9.96 BDNF CCKBR CNR1 CRH HTR2C NR3C1
3 nervous system MP:0003631 9.93 BDNF CCKBR CNR1 CRH CRHR1 HTR1A
4 no phenotypic analysis MP:0003012 9.5 BDNF CNR1 CRH CRHR1 HTR1A NR3C1
5 normal MP:0002873 9.23 BDNF CNR1 CRH CRHR1 NR3C1 OPRL1
Sources

Drugs & Therapeutics for Anxiety

About this section

Drugs for Anxiety (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1089)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Tangerine Approved Phase 4
2
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
3
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
4
Reboxetine Approved, Experimental Phase 4 98769-81-4, 71620-89-8 123628 65856
5
Abacavir Approved, Investigational Phase 4 136470-78-5 441300 65140
6
Trimebutine Approved Phase 4 39133-31-8
7
Drospirenone Approved Phase 4 67392-87-4 68873
8
Menotropins Approved Phase 4 61489-71-2, 9002-68-0 5360545
9
Prucalopride Approved Phase 4 179474-81-8
10
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
11
Tiagabine Approved, Investigational Phase 4 115103-54-3 60648
12
Lorazepam Approved Phase 4 846-49-1 3958
13
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
14
Disulfiram Approved Phase 4 97-77-8 3117
15
Chamomile Approved, Experimental, Investigational Phase 4
16
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
17
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
18
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
19
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
20
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
21
Memantine Approved, Investigational Phase 4 19982-08-2 4054
22
Clonidine Approved Phase 4 4205-90-7 2803
23
Caffeine Approved Phase 4 58-08-2 2519
24
Ribavirin Approved Phase 4 36791-04-5 37542
25
Desipramine Approved, Investigational Phase 4 50-47-5 2995
26
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
27
Lofexidine Approved, Investigational Phase 4 31036-80-3 30668
28
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
29
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
30
Clozapine Approved Phase 4 5786-21-0 2818
31
Flurazepam Approved, Illicit, Investigational Phase 4 17617-23-1 3393
32
Nitrazepam Approved Phase 4 146-22-5 4506
33
Azithromycin Approved Phase 4 83905-01-5 447043 55185
34
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
35
Atropine Approved, Vet_approved Phase 4 51-55-8, 5908-99-6 174174
36
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
37
Desflurane Approved Phase 4 57041-67-5 42113
38
Dolutegravir Approved Phase 4 1051375-16-6 54726191
39
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
40
Benzydamine Approved Phase 4 100-46-9, 642-72-8 7504
41
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
42
Ranibizumab Approved Phase 4 347396-82-1 459903
43
Ondansetron Approved Phase 4 99614-02-5 4595
44
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
45
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
46
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
47
Tetracaine Approved, Vet_approved Phase 4 94-24-6 5411
48
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
49
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
50
Bromfenac Approved Phase 4 91714-94-2 60726

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Unknown status NCT02294305 Phase 4 Vortioxetine;Placebo
2 Group Mindfulness-Based Cognitive Therapy for the Treatment of Late-Life Depression and Anxiety Symptoms in Primary Care: A Randomized Controlled Trial Unknown status NCT02777905 Phase 4
3 The Effect and Reliability of Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders Unknown status NCT03122158 Phase 4 Escitalopram
4 Randomized，Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
5 Phase 4 Study of The Effect of Sihogayonggolmoryeo-tang on the Anxiety of Hwa-byung : A Randomized, Double Blind, Placebo-control Trial Unknown status NCT01362114 Phase 4 SIHOGAYONGGOLMORYU TANG EXTRACT GRAN
6 Comparison of 2 Methods to Reduce Postoperative Pain in Children and a Comparison of 3 Methods of Preoperative Education Intervention to Reduce Anxiety in Children and Their Family Unknown status NCT00643032 Phase 4
7 Topiramate Augmentation to a Selective Serotonin Re-uptake Inhibitor (SSRI) in Treatment-Resistant Generalized Social Phobia: A Double-Blind Placebo -Controlled Trial. Unknown status NCT00182455 Phase 4 Topiramate;Placebo
8 Impact of 50% Nitrous Oxide Inhalation on Pain and Anxiety Induced by Lumbar Puncture: a Multicenter Double-blind Randomized Controlled Trial Unknown status NCT03228628 Phase 4 Fixed 50:50 mixture of nitrous oxide and oxygen
9 Escitalopram Treatment of Major Depression in Diabetes Mellitus: An Open Label Unknown status NCT00650897 Phase 4 Escitalopram
10 Double Blind, Placebo-Controlled Trial of THC as add-on Therapy for PTSD Unknown status NCT00965809 Phase 4 Tetrahydrocannabinol
11 The Effect of Music Over the Tolerance to Colonoscopy ¿Does it Reduce the Discomfort, the Anxiety and the Need of Sedation? Multicentric Randomized Controlled Trial. Unknown status NCT01285284 Phase 4
12 Assessment of the Effect of Moxonidine and Diet on Cardiac, Renal and Endothelial Function in Young Subjects With Abdominal Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
13 Effects of a Probiotic Supplement on Symptoms of ADHD and Anxiety in Children Unknown status NCT02545634 Phase 4
14 The Short and Long Term Effects of Perioperative Pregabalin Use on Functional Rehabilitation, Pain Outcomes and Anxiety Following Total Hip Arthroplasty: A Randomized, Double-Blind, Placebo-Controlled Trial. Unknown status NCT00762099 Phase 4 Pregabalin;Placebo
15 Double-blind Randomized Clinical Trial to Compare Presurgery Anxiolysis in Children Treated With Hydroxyzine Versus Non-pharmacological Intervention (Distractoria Technique Clown) Unknown status NCT03324828 Phase 4 Hydroxyzine
16 Effect of Additive Lorazepam on Patient Satisfaction as a Premedication in Diagnostic Flexible Bronchoscopy Unknown status NCT01121055 Phase 4 Lorazepam;Control
17 Impact of 50% Nitrous Oxide Inhalation on Pain and Anxiety Induced by Lumbar Puncture: a Double-blind Randomized Controlled Trial Unknown status NCT02243826 Phase 4 50:50 mixture of nitrous oxide/oxygen
18 The Effect of Three Different Interventions on the Recovery Agitation and Delirium in the Pacu Pediatric Patients Unknown status NCT03426020 Phase 4
19 Effectiveness of Oral Midazolam for Sedation in Patients Undergoing Upper Gastrointestinal Endoscopy Unknown status NCT01990937 Phase 4 Oral midazolam
20 Clinical Study of Wuling Capsule in the Treatment of Chronic Tinnitus With Emotional Disorder Unknown status NCT03674853 Phase 4 Wuling Capsule;Oryzanol
21 Effect Site Controlled, Reaction Time Safeguarded, Patient Maintained Sedation With Propofol A) in Oral Surgery Patients B) in General Dentistry Patients C) in Colonoscopy Patients Unknown status NCT00355693 Phase 4
22 Evaluation of the Efficacy of Repetitive Transcranial Magnetic Stimulation on Cognitive, Anxiety and Depressive Symptoms in Patients Diagnosed With Major Depressive Disorder Unknown status NCT02213016 Phase 4
23 A Based on PEEG and PET Study of Anxiolytic Treatment to Improve Cognitive Function in Patients With Alzheimer Disease Unknown status NCT03151382 Phase 4 Tandospirone Citrate;Donepezil Hydrochloride
24 A Randomized , Controlled, Doulbe Blind Placebo Trial To Evaluate The Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children Unknown status NCT00770627 Phase 4
25 A Double-Blind, Placebo-Controlled Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
26 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in PCOS Patients. Unknown status NCT01246310 Phase 4
27 The Use of Oral N-Acetyl Cysteine for the Treatment of Chronic Sinonasal Symptoms: A Randomized, Double-Blind, Placebo-Controlled Trial Unknown status NCT00866866 Phase 4 N-Acetyl Cysteine;Placebo
28 Study Proposal - A Randomized Double-blinded Study Comparing Adding Etoricoxib Versus Placebo to Female Patients With Fibromyalgia-analysis of Organic and Psychiatric Measures Unknown status NCT00755521 Phase 4 etoricoxib
29 The Role of Inflammatory and Stress Response in the Pathogenesis of Cognitive Dysfunction After Cardiac Surgery Unknown status NCT02767713 Phase 4 Dexamethasone
30 Early Pharmacological Intervention With Diazepam in the Emergency Room Setting to Prevent Posttraumatic Stress Disorder (PTSD). Unknown status NCT01221883 Phase 4 Diazepam
31 Comparison Between the Analgesic Affects of Tramadol® and "Verbal Anesthesia" on Pain Management Associated With the Insertion of Jaydess® in Nulliparous Women Unknown status NCT02706509 Phase 4 Tramadol
32 Effects of Perampanel on Cognition and Electroencephalography in Patients With Epilepsy Unknown status NCT02900755 Phase 4 Perampanel
33 The Effect of 21-Days Intranasal Oxytocin on Clinical Symptoms and Social Function in Patients With Post Traumatic Stress Disorder (PTSD), a Randomized Controled Trail Unknown status NCT02336568 Phase 4 Oxytoine;PLACEBO
34 The Clinical Efficacy and Safety of Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Unknown status NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
35 Randomised Controlled Study Comparing Use of Popofol Plus Fentanyl Versus Midazolam Plus Fentanyl as Sedation in Diagnostic Endoscopy in Patients With Advanced Liver Disease. Unknown status NCT03063866 Phase 4 Propofol;Midazolam;Fentanyl
36 A Comparison of Two Doses of Intranasal Dexmedetomidine for Premedication in Children - a Double- Blind Randomised Controlled Trial Unknown status NCT02459509 Phase 4 Dexmedetomidine
37 Assessment of the Effectiveness of a Program of Preparation to Pregnancy and Delivery Unknown status NCT01155804 Phase 4
38 Impact of VSL#3 on Infants Colics as Assessed by Average Crying Time Unknown status NCT01869426 Phase 4
39 Pharmacological Anxiolysis With Promethazine as an Adjunctive Therapy for Acute Low Back Pain in the Adult Emergency Department Unknown status NCT01129934 Phase 4 Morphine-Promethazine;morphine
40 The ED50 of DEX for Providing Sedation in Different Female Age Group Unknown status NCT02773017 Phase 4 Dexmedetomidine A;Dexmedetomidine B;Dexmedetomidine C
41 Does Massage With or Without Aromatherapy Reduce Infant's Distress After Craniofacial Surgery? A Randomized Controlled Trial Unknown status NCT00624637 Phase 4
42 Randomized, Multicentric and Prospective Clinical Trial to Check the Cost-effectiveness of Corifollitropin Alfa vs. Recombinant FSH and/or HP-hMG Unknown status NCT02213627 Phase 4 Corifollitropin alfa;Recombinant FSH;HP-hMG
43 The Effect of Intracervical Lidocaine Versus Intramuscular Diclofenac for Pain Relief During Hysterosalpingography Among Infertile Women In A Tertiary Hospital In Kano: A Randomized Controlled Trial Unknown status NCT02918812 Phase 4 Intracervical lidocaine;Intramuscular Diclofenac
44 Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate the Efficacy and Tolerability of the Combination of Soy Isoflavones and Red Clover Extract (FITOGYN) in the Treatment of the Hot Flushes in Menopausal Women. Unknown status NCT01116310 Phase 4 Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L);Placebo
45 Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment Unknown status NCT02760940 Phase 4 oral liposomal iron
46 Methylphenidate in Healthy Young Adults Unknown status NCT00815841 Phase 4 METHYLPHENIDATE
47 Prucalopride Versus Placebo in Functional Dyspepsia With Delayed Gastric Emptying Unknown status NCT02510976 Phase 4 prucalopride;placebo
48 Assessment and Follow Up Study of Children and Adolescent With Bipolar Disorder Unknown status NCT01000402 Phase 4 Psychopharmacotherapy
49 Botulinum A Toxin Intravesical Injections Versus Bladder Overdistension in the Treatment of Patients With Painful Bladder Syndrome: A Prospective Randomized Study Unknown status NCT01157507 Phase 4 Intravesical injection of Botulinum A Toxin;Placebo
50 Enhancement of Learning Associated Neural Plasticity by Selective Serotonin Reuptake Inhibitors Unknown status NCT02753738 Phase 4 Escitalopram;Placebo

Search NIH Clinical Center for Anxiety

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Amobarbital
AMOBARBITAL NA PWDR
Amobarbital Sodium
bromodiphenhydramine
Bromodiphenhydramine hydrochloride
Buspirone
buspirone hydrochloride
Chlordiazepoxide
Chlordiazepoxide Hydrochloride
Chlormezanone
Chlorpromazine
Chlorpromazine hydrochloride
clorazepate
Clorazepate Dipotassium
Diphenhydramine
Diphenhydramine Citrate
Diphenhydramine Hydrochloride
Doxepin
Doxepin Hydrochloride
halazepam
Hydroxyzine
Hydroxyzine Hydrochloride
Hydroxyzine Pamoate
HYPERICUM PERFORATUM (ST. JOHN'S WORT)
Kava preparation
Lorazepam
Meprobamate
Methotrimeprazine
Midazolam
Midazolam Hydrochloride
Nortriptyline
Nortriptyline Hydrochloride
Oxazepam
Prazepam
Prochlorperazine
Prochlorperazine Edisylate Salt
Prochlorperazine Maleate

Cochrane evidence based reviews: anxiety disorders

Sources

Genetic Tests for Anxiety

About this section

Genetic tests related to Anxiety:

# Genetic test Affiliating Genes
1 Anxiety 29 SLC6A4
Sources

Anatomical Context for Anxiety

About this section

MalaCards organs/tissues related to Anxiety:

40
Brain, Testes, Breast, Heart, Amygdala, Lung, Prostate
Sources

Publications for Anxiety

About this section

Articles related to Anxiety:

(show top 50) (show all 43441)
# Title Authors PMID Year
1
Duplication of GTF2I results in separation anxiety in mice and humans. 56 61
22578324 2012
2
Amygdalar and hippocampal substrates of anxious temperament differ in their heritability. 56 61
20703306 2010
3
A key role for orexin in panic anxiety. 56 61
20037593 2010
4
Familial clustering of major depression and anxiety disorders in Australian and Dutch twins and siblings. 56 61
16354503 2005
5
Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice. 61 56
16244648 2005
6
Effects of progressive muscle relaxation on anxiety and sleep quality in patients with COVID-19. 61 42
32379667 2020
7
Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. 56
21350482 2011
8
Financial and psychological risk attitudes associated with two single nucleotide polymorphisms in the nicotine receptor (CHRNA4) gene. 56
19693267 2009
9
Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders. 61 46
19370765 2009
10
Association analysis of monoamine genes with measures of depression and anxiety in a selected community sample of siblings. 56
15729745 2005
11
A genome scan of neuroticism in nicotine dependent smokers. 56
15389754 2005
12
Genetic variants implicated in personality: a review of the more promising candidates. 56
15389772 2004
13
Genome-wide linkage analysis of a composite index of neuroticism and mood-related scales in extreme selected sibships. 56
15351774 2004
14
Meta-analysis of the association between a serotonin transporter promoter polymorphism (5-HTTLPR) and anxiety-related personality traits. 56
15108187 2004
15
A meta-analysis of the association between the serotonin transporter gene polymorphism (5-HTTLPR) and trait anxiety. 56
14966478 2004
16
Linkage analysis of extremely discordant and concordant sibling pairs identifies quantitative-trait loci that influence variation in the human personality trait neuroticism. 56
12612864 2003
17
Tridimensional personality questionnaire trait of harm avoidance (anxiety proneness) is linked to a locus on chromosome 8p21. 56
12555238 2003
18
Toward a molecular architecture of personality. 56
12642172 2003
19
Association and linkage of anxiety-related traits with a functional polymorphism of the serotonin transporter gene regulatory region in Israeli sibling pairs. 56
10822353 2000
20
Role of the serotonin transporter promoter polymorphism in anxiety-related traits. 56
9783565 1998
21
An association study of a functional polymorphism of the serotonin transporter gene with personality and psychiatric symptoms. 56
9774781 1998
22
Anxiety proneness linked to epistatic loci in genome scan of human personality traits. 56
9674977 1998
23
Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. 56
8929413 1996
24
The correlation of patients' anxiety after a liver or kidney transplantation with functional and self-reported work ability. 42
32358401 2020
25
Effect of high-quality nursing intervention on anxiety and depression in patients with chronic heart failure companied malnutrition: A protocol for systematic review and meta-analysis. 42
32481393 2020
26
An association analysis of circadian genes in anxiety disorders. 61 54
20122683 2010
27
The CRF system, stress, depression and anxiety-insights from human genetic studies. 54 61
20010888 2010
28
Effect of tryptophan hydroxylase-2 gene variants on amygdalar and hippocampal volumes. 61 54
20331984 2010
29
A genetic variant BDNF polymorphism alters extinction learning in both mouse and human. 61 54
20075215 2010
30
Dose-dependent effects of the CRF(1) receptor antagonist R317573 on regional brain activity in healthy male subjects. 54 61
19911168 2010
31
Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. 61 54
19615387 2010
32
The endocannabinoid system and the treatment of mood and anxiety disorders. 61 54
19839936 2009
33
The serotonin-1A receptor in anxiety disorders. 61 54
19423077 2009
34
Soluble corticotropin-releasing hormone receptor 2alpha splice variant is efficiently translated but not trafficked for secretion. 61 54
19520785 2009
35
Sympathetic activity relates to adenosine A(2A) receptor gene variation in blood-injury phobia. 54 61
18629431 2009
36
How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale. 61 54
19273493 2009
37
Research in anxiety disorders: from the bench to the bedside. 54 61
19327970 2009
38
Blushing propensity in social anxiety disorder: influence of serotonin transporter gene variation. 61 54
18629430 2009
39
Variant BDNF Val66Met polymorphism affects extinction of conditioned aversive memory. 54 61
19339601 2009
40
Association between the CYP2D6*4 polymorphism and depression or anxiety in the elderly. 54 61
19374513 2009
41
Consequences of post-weaning social isolation on anxiety behavior and related neural circuits in rodents. 61 54
19738931 2009
42
The BDNF Val66Met polymorphism affects amygdala activity in response to emotional stimuli: evidence from a genetic imaging study. 61 54
18603005 2008
43
Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder. 54 61
18384079 2008
44
The BDNF Val66Met polymorphism and smoking. 61 54
18602452 2008
45
Role of metabotropic glutamate receptors in the control of neuroendocrine function. 54 61
18616955 2008
46
5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. 54 61
18047755 2008
47
The role of the glutamatergic system in posttraumatic stress disorder. 61 54
18622363 2008
48
Polymorphisms in the FKBP5 gene region modulate recovery from psychosocial stress in healthy controls. 61 54
18702710 2008
49
Association study between the serotonin 1A receptor (HTR1A) gene and neuroticism, major depression, and anxiety disorders. 54 61
18163385 2008
50
Characterization of (R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one as a positive allosteric modulator of GABAB receptors. 54 61
18536733 2008
Sources

Variations for Anxiety

About this section

ClinVar genetic disease variations for Anxiety:

6 (show all 11) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 46;XY;t(6;12)(q14;q24);20p+dncomplex Pathogenic 267833
2 46;XX;t(2;11)(q11.2;p13)dnTranslocation Pathogenic 267861
3 46;XY;t(2;6)(q33;q21)dnTranslocation Pathogenic 267885
4 46;XY;t(1;2)(p34.2;q35)dnTranslocation Pathogenic 267887
5 USH2A NM_007123.5(USH2A):c.2299del (p.Glu767fs)deletion Pathogenic/Likely pathogenic 2351 rs80338903 1:216420437-216420437 1:216247095-216247095
6 HMBS NM_000190.4(HMBS):c.958del (p.Ala320fs)deletion Likely pathogenic 373971 rs1057518806 11:118963865-118963865 11:119093155-119093155
7 OTX2 NM_021728.4(OTX2):c.191_193delinsGG (p.Leu64fs)indel Likely pathogenic 523565 rs1555350397 14:57270986-57270988 14:56804268-56804270
8 ADAR NM_001111.5(ADAR):c.1646C>A (p.Ala549Asp)SNV Uncertain significance 598987 rs1557882064 1:154571017-154571017 1:154598541-154598541
9 USH2A NM_206933.3(USH2A):c.5003G>T (p.Gly1668Val)SNV Uncertain significance 598989 rs1265349835 1:216258204-216258204 1:216084862-216084862
10 MYH8 NM_002472.3(MYH8):c.5743A>G (p.Ile1915Val)SNV Uncertain significance 598988 rs1216879928 17:10293842-10293842 17:10390525-10390525
11 CR1 NM_000651.6(CR1):c.6283C>A (p.His2095Asn)SNV Uncertain significance 812547 1:207783021-207783021 1:207609676-207609676

Copy number variations for Anxiety from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 139649 2 185171337 185512459 Deletion ZNF804A anxiety disorder
Sources

Expression for Anxiety

About this section
Search GEO for disease gene expression data for Anxiety.
Sources

Pathways for Anxiety

About this section

Pathways related to Anxiety according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Peptide ligand-binding receptors 65
Show member pathways
 13.3 OPRL1 NR3C1 NPS HTR2C HTR2A HTR1A
2
G-Beta Gamma Signaling 63
Show member pathways
 12.78 HTR2C HTR2A CRHR1 CRH CNR1 BDNF
4
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.91 TPH2 TPH1 SLC6A4 NR3C1 HTR2A HTR1A
5
Monoamine GPCRs 1
Show member pathways
 11.75 HTR2C HTR2A HTR1A
6
Imipramine/Desipramine Pathway, Pharmacokinetics 60
Show member pathways
 11.7 SLC6A4 CYP3A4 CYP2D6
7
GPCRs, Other 1
11.68 HTR2A CNR1 CCKBR
8
Tryptophan metabolism 1 36
Show member pathways
 11.62 TPH2 TPH1 CYP3A4
9
Serotonergic synapse 36
11.56 TPH2 TPH1 SLC6A4 HTR2C HTR2A HTR1A
10
Methylphenidate Pathway, Pharmacodynamics 60
Show member pathways
 10.91 TPH2 SLC6A4 HTR1A
11
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling 1
10.85 HTR2C HTR2A
12
Ondansetron Pathway, Pharmacokinetics/Pharmacodynamics 60
Show member pathways
 10.73 CYP3A4 CYP2D6
13
Cell-type Dependent Selectivity of CCK2R Signaling 1
10.57 CNR1 CCKBR
14
Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics 60
10.55 TPH2 TPH1 SLC6A4 HTR2C HTR2A HTR1A
15
Glucocorticoid Pathway (HPA Axis), Pharmacodynamics 60
10.25 CRHR1 CRH
Sources

GO Terms for Anxiety

About this section

Cellular components related to Anxiety according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.8 SLC6A4 OPRL1 HTR2C HTR2A HTR1A CRHR1
2 synapse GO:0045202 9.63 SLC6A4 HTR2C HTR2A HTR1A CRH CNR1
3 neuron projection GO:0043005 9.35 TPH2 TPH1 SLC6A4 OPRL1 CRHR1
4 integral component of presynaptic membrane GO:0099056 8.8 SLC6A4 HTR2A CNR1

Biological processes related to Anxiety according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.1 OPRL1 NR3C1 HTR2C HTR2A HTR1A CRHR1
2 chemical synaptic transmission GO:0007268 9.93 HTR2C HTR2A HTR1A CRH
3 response to drug GO:0042493 9.93 SLC6A4 HTR2C HTR2A CRH BDNF
4 G protein-coupled receptor signaling pathway GO:0007186 9.81 OPRL1 NPS HTR2C HTR2A HTR1A CRHR1
5 learning or memory GO:0007611 9.79 CRH CNR1 BDNF
6 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.78 HTR2C HTR2A CCKBR
7 sensory perception of pain GO:0019233 9.77 OPRL1 HTR2A CNR1
8 positive regulation of fat cell differentiation GO:0045600 9.76 TPH1 HTR2C HTR2A
9 circadian rhythm GO:0007623 9.67